TY - JOUR
T1 - Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia
T2 - International Consensus Report
AU - Al-Samkari, Hanny
AU - Kasthuri, Raj S.
AU - Mager, Hans Jurgen
AU - Zhou, Jenny Y.
AU - Serra, Marcelo M.
AU - Samuelson-Bannow, Bethany T.
AU - Van Doren, Layla N.
AU - Piccirillo, Jay F.
AU - Clancy, Marianne S.
AU - McCrae, Keith R.
AU - Thomas, Sonia M.
AU - Riera-Mestre, Antoni
AU - Pishko, Allyson M.
AU - Sewaralthahab, Sarah
AU - Gossage, James R.
AU - Iyer, Vivek N.
AU - Hermans, Cedric
AU - Hammill, Adrienne
AU - Winship, Ingrid
AU - Mei-Zahav, Meir
AU - von Drygalski, Annette
AU - Olitsky, Scott
AU - Faughnan, Marie E.
N1 - Publisher Copyright:
© 2025 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
PY - 2025/10
Y1 - 2025/10
N2 - Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease-modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT-specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician-investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria: Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.
AB - Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease-modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT-specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician-investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria: Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.
KW - HHT
KW - Hereditary hemorrhagic telangiectasia
KW - Osler-Weber-Rendu
KW - anemia
KW - angiogenesis
KW - bleeding
KW - epistaxis
KW - gastrointestinal bleeding
KW - iron deficiency
UR - https://www.scopus.com/pages/publications/105010576738
U2 - 10.1002/ajh.70011
DO - 10.1002/ajh.70011
M3 - Review article
C2 - 40662351
AN - SCOPUS:105010576738
SN - 0361-8609
VL - 100
SP - 1813
EP - 1827
JO - American journal of hematology
JF - American journal of hematology
IS - 10
ER -